Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Operating Leases (2019 - 2025)

Eton Pharmaceuticals' Operating Leases history spans 6 years, with the latest figure at $107000.0 for Q4 2024.

  • For Q4 2024, Operating Leases rose 386.36% year-over-year to $107000.0; the TTM value through Dec 2024 reached $107000.0, up 386.36%, while the annual FY2024 figure was $107000.0, 386.36% up from the prior year.
  • Operating Leases for Q4 2024 was $107000.0 at Eton Pharmaceuticals, down from $126000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $145000.0 in Q2 2024 and bottomed at $15000.0 in Q4 2021.
  • The 5-year median for Operating Leases is $82500.0 (2021), against an average of $76875.0.
  • The largest annual shift saw Operating Leases tumbled 84.85% in 2021 before it surged 613.33% in 2022.
  • A 5-year view of Operating Leases shows it stood at $99000.0 in 2020, then crashed by 84.85% to $15000.0 in 2021, then soared by 613.33% to $107000.0 in 2022, then tumbled by 79.44% to $22000.0 in 2023, then skyrocketed by 386.36% to $107000.0 in 2024.
  • Per Business Quant, the three most recent readings for ETON's Operating Leases are $107000.0 (Q4 2024), $126000.0 (Q3 2024), and $145000.0 (Q2 2024).